Navigation Links
Concentration, timing and interactions are key when it comes to dietary compounds

This release is available in Spanish.

Agricultural Research Service (ARS) chemist Thomas Wang, who specializes in cancer prevention research, has reported evidence that for some dietary compounds, length of exposure over time may be key to whether or not ingestion leads to a beneficial, or detrimental, effect.

Scientists do not know exactly why one person develops cancer and another does not. But they do know that certain nutrients might increase or decrease cancer risk. There are "layers" of factors involved in the development of cancer, and Wang is studying the layers involving peoples' diet complexity and gene expression.

Wang works at the ARS Diet, Genomics and Immunology Laboratory, part of the Beltsville (Md.) Human Nutrition Research Center. He published a complementary cell-culture and animal-model study showing that concentrations of resveratrol--a highly bioactive compound found in grapes and other plant foods--actually turned out to be a double-edged sword when it came to mitigating cancer risk.

First, Wang exposed human prostate cancer cells to resveratrol and found that it inhibited the cells' growth. He further tested the cells' gene expression. Then Wang tested the effects of resveratrol on a group of laboratory animals that had sex-hormone-dependent tumor cells.

Half of those animals were fed a daily diet that included 3 to 6 milligrams of purified resveratrol (equal to roughly the amount in five glasses of wine or grape juice). At first, the tumor cells in the resveratrol-fed lab animals grew slower. But as the animals continued to consume resveratrol, there was an increase in blood vessels developing around the tumors of the resveratrol-fed animals, effectively setting up a system of feeding the tumors.

The study, published in the journal Carcinogenesis, showed that the concentration of the plant compound is important, but so is length of exposure, according to the authors.


Contact: Rosalie Marion Bliss
United States Department of Agriculture-Research, Education, and Economics

Related medicine news :

1. North Shore-LIJ Becomes NY's First Health System to Require New Nurses to Get Bachelor's Degree
2. Endoscopic ultrasound evaluation is associated with improved outcomes in pancreatic cancer patients
3. New surgery improves outcomes for severe flat foot deformity
4. Madison Avenue Welcomes Nineteen New Stores In First Half Of 2010
5. TowerStrides Inc. Becomes Oracle PartnerNetwork Gold Level Partner
6. Pet Insurance from Trupanion Becomes Available in Hawaii
7. Reading Comes Easier for Kids When Rovers Around
8. Mercy Ships Releases Abel Dalome Just in Time for Father's Day - A Father's Dream Becomes a Reality
9. FileHold Document Management Software welcomes Click2ScanLtd. as a Value Added Re-sellers in the UK
10. Size matters -- when it comes to DNA
11. Breakthrough In Liposuction Comes To New York's Capital District
Post Your Comments:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... non-traumatic limb amputations in the United States. Podiatrists are well aware that psychology-based ... adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic foot. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... 2015 , ... TCS Healthcare Technologies (TCS), a leading provider ... is pleased to announce that VIP Care Services, a Caprock Health Group affiliate ... Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY Complete ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... BOSTON , December 1, 2015 Russia ... phase III clinical trials. 70% of new drugs registered in ... trials in Russia . --> Russia has ... trials. 70% of new drugs registered in Europe ... . --> Russia has always been ...
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: